<DOC>
	<DOCNO>NCT00211198</DOCNO>
	<brief_summary>The purpose research study evaluate effective ONTAK treatment cutaneous T-cell Lymphoma ( CTCL ) determine whether presence type protein call CD25 cancer cell make difference body respond treatment . The hypothesis difference response rate patient whose tumor cell CD25 positive negative .</brief_summary>
	<brief_title>Study ONTAK® Treat Cutaneous T-Cell Lymphoma ( CTCL )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Denileukin diftitox</mesh_term>
	<criteria>Persistent recurrent cutaneous Tcell lymphoma ( CTCL ) Stage IBIVA define TNM stag . Pathologic proven diagnosis ( cytologically confirm ) CTCL document patient history . Preserved organ function : Creatinine and/or Liver Function level &lt; 1.5 time institutional upper limit normal ( ULN ) . Adequate liver function indicate bilirubin &lt; equal 1.5 time ULN , ALT &lt; equal 2 time ULN , AST &lt; equal 2 time ULN . Albumin &gt; 3.0 g/dL Adequate renal function indicate SCr &lt; equal 2.5 mg/dl . ECOG performance status 02 . Women childbearing potential screened pregnancy prior treatment utilize effective contraceptive method ( e.g . barrier ) treatment period . Patients age 18 willing able provide Informed Consent . Pathology consistent peripheral Tcell lymphoma . Stage IVB ( visceral involvement CTCL , lymph node involvement ) . History Human Immunodeficiency Virus ( HIV ) , Hepatitis B Hepatitis C infection . Patients pregnant breast feed . Allergy history allergy diphtheria toxin IL2 . Previous ONTAK® usage . Unstable cardiovascular disease . Patients receive systemic topical antineoplastic therapy investigational medication within past 14 day . Exception : Clear evidence disease progression require immediate intervention absence ongoing toxicity prior therapy . Ongoing deep vein thrombosis diagnosis deep vein thrombosis le 3 month prior protocol enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>Cutaneous</keyword>
	<keyword>T-cell lymphoma</keyword>
	<keyword>ONTAK</keyword>
	<keyword>CD25</keyword>
</DOC>